Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

This study has been withdrawn prior to enrollment.
(insufficient enrollment)
Wyeth is now a wholly owned subsidiary of Pfizer
Mundipharma K.K.
Information provided by:
Charite University, Berlin, Germany Identifier:
First received: July 14, 2010
Last updated: March 15, 2011
Last verified: June 2010
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: April 2014
  Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)